US EditionUZLeuven and VIB-KU Leuven Announce First Patient Treated in Ground-Breaking Malignant Melanoma Study
- On March 31, 2025, UZ Leuven and VIB-KU Leuven, collaborating with Seattle-based Presage Biosciences Inc, announced the treatment of the first patient in a novel pilot study for metastatic or inoperable stage III melanoma.
- This study aims to identify drugs with enhanced combination effects for first-line melanoma patients undergoing anti-PD1 systemic therapy, particularly those who are anti-PD1 refractory.
- The study utilizes Presage's Comparative In Vivo Oncology microinjection device to spatially microdose up to 7 different drugs intratumorally within a patient's tumor, while the patient is also undergoing anti-PD1 systemic therapy.
- Prof. Dr. Oliver Bechter of UZ Leuven stated, "This is the first study of its kind studying locally administered anti-cancer drugs in combination with systemic anti-PD1 therapy in first line treated melanoma patients," while Dr. Chris Marine of VIB-KU Leuven Center for Cancer Biology added, "The introduction of this groundbreaking technology has ushered us into a new frontier in translational research, enabling us to translate our most promising laboratory discoveries directly into patients."
- By combining CIVO technology with advanced spatial multi-omics and single-cell spatial technology, the study seeks to gain an unparalleled understanding of tumor biology, drug target engagement, and patient tumor microenvironment response to accelerate the development of new treatments and provide data-driven insights to pharma and biotech partners.
Insights by Ground AI
Does this summary seem wrong?
12 Articles
12 Articles
All
Left
Center
7
Right
Helena Independent Record+11 Reposted by 11 other sources
UZLeuven and VIB-KU Leuven Announce First Patient Treated in Ground-Breaking Malignant Melanoma Study
SEATTLE, March 31, 2025 /PRNewswire/ -- UZ Leuven and VIB-KU Leuven, in collaboration with Seattle-based Presage Biosciences, are announcing the first patient treated in a Non-randomized (phase I – pharmacodynamic only) open label, single center single arm interventional pilot study.…
·Helena, United States
Read Full ArticleCoverage Details
Total News Sources12
Leaning Left0Leaning Right0Center7Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
